tbuckley/cabot-search huggingface dataset:
Evaluation of an artificial intelligence-based medical device for diagnosis of autism spectrum disorder
Authors: Jonathan T. Megerian, Sangeeta Dey, Raun D. Melmed, Daniel L. Coury, Marc Lerner, Christopher J. Nicholls, Kristin Sohl, Rambod Rouhbakhsh, Anandhi Narasimhan, Jonathan Romain, Sailaja Golla, Safiullah Shareef, Andrey Ostrovsky, Jennifer Shannon, Colleen Kraft, Stuart Liu-Mayo, Halim Abbas, Diana E. Gal-Szabo, Dennis P. Wall, Sharief Taraman
Journal: npj Digital Medicine (2022)

Autism spectrum disorder (ASD) can be reliably diagnosed at 18 months, yet significant diagnostic delays persist in the United States. This double-blinded, multi-site, prospective, active comparator cohort study tested the accuracy of an artificial intelligence-based Software as a Medical Device designed to aid primary care healthcare providers (HCPs) in diagnosing ASD. The Device combines behavioral features from three distinct inputs (a caregiver questionnaire, analysis of two short home videos, and an HCP questionnaire) in a gradient boosted decision tree machine learning algorithm to produce either an ASD positive, ASD negative, or indeterminate output. This study compared Device outputs to diagnostic agreement by two or more independent specialists in a cohort of 18-72-month-olds with developmental delay concerns (425 study completers, 36% female, 29% ASD prevalence). Device output PPV for all study completers was 80.8% (95% confidence intervals (CI), 70.3%-88.8%) and NPV was 98.3% (90.6%-100%). For the 31.8% of participants who received a determinate output (ASD positive or negative) Device sensitivity was 98.4% (91.6%-100%) and specificity was 78.9% (67.6%-87.7%). The Device's indeterminate output acts as a risk control measure when inputs are insufficiently granular to make a determinate recommendation with confidence. If this risk control measure were removed, the sensitivity for all study completers would fall to 51.6% (63/122) (95% CI 42.4%, 60.8%), and specificity would fall to 18.5% (56/303) (95% CI 14.3%, 23.3%). Among participants for whom the Device abstained from providing a result, specialists identified that 91% had one or more complex neurodevelopmental disorders. No significant differences in Device performance were found across participants' sex, race/ethnicity, income, or education level. For nearly a third of this primary care sample, the Device enabled timely diagnostic evaluation with a high degree of accuracy. The Device shows promise to significantly increase the number of children able to be diagnosed with ASD in a primary care setting, potentially facilitating earlier intervention and more efficient use of specialist resources.
ANTIBIOTIC PROPHYLAXIS FOR COLORECTAL ENDOSCOPIC SUBMUCOSAL DISSECTION- IS IT DOGMA?
Authors: K. Siggens, H. Htet, S.P. Aslam, M. Abdelrahim, S. Subramaniam, P. Bhandari
Journal: Endoscopy (2022)

Aims Antibiotic prophylaxis is widely used during endoscopic submucosal dissection (ESD) which usually mandates hospital admission post-procedure. There is also suggestion that low rectal resections carry higher risk of sepsis. ESD is associated with high risk of bleeding and perforation. This can result in the need for admission. In our centre, antibiotic prophylaxis and admission is not a routine part of patient care. In this study we looked to review our outcomes.
CONVERSION OF A MALFUNCTIONING PERCUTANEOUS CHOLECYSTOSTOMY INTO AN EUS-GUIDED CHOLECYSTOGASTROSTOMY
Authors: I. Omella Usieto, B. Agudo Castillo, M. Gonzalez-Haba Ruiz
Journal: Endoscopy (2022)

Percutaneous gallbladder drainage (PGD) is the treatment of choice for acute cholecystitis in high risk surgical patients. EUS-guided transmural drainage (EUS-GBD) has shown similar results with a lower rate of complications. In addition, as its role as initial approach, EUS-GBD may convert a pre existing PGD into an internal drain, reducing common complications (ie catheter dislodgement, cellulitis, fistula formation and infection) and increasing patient’s comfort. We hereby report a case of successful EUS-GBD conversion in a patient with PGD and recurrent complications.
EVALUATION OF ULCERATIVE COLITIS ENDOSCOPIC MAYO SCORE WITH ARTIFICIAL INTELLIGENCE
Authors: H.T. Kani, I. Ergenc, G. Polat, Y. Ozen Alahdab, A. Temizel, O. Atug
Journal: Endoscopy (2022)

Aims Multilayer artificial neural networks are artificial intelligence (AI) algorithms with high predictive power that allow processing large volumes of data sets. Ulcerative colitis (UC) Endoscopic Mayo Score (EMS) is a subjective assessment that varies between the endoscopists (1, 2). Our aim was to develop an AI algorithm to evaluate endoscopist-independent EMS with high accuracy and minimize the subjectivity.
189P Pharmacokinetics (PK) of sacituzumab govitecan (SG) in patients (Pts) with metastatic triple-negative breast cancer (mTNBC) and other solid tumors
Authors: A.G. Sathe, I. Singh, P. Singh, P. Diderichsen, X. Wang, P. Chang, S-C. Phan, S. Girish, A.A. Othman
Journal: Annals of Oncology (2022)
170P Long-term survival of breast cancer patients with brain metastases: Subanalysis of the BMBC registry
Authors: K. Riecke, E. Laakmann, T. Neunhöffer, T-W. Park-Simon, R. Weide, M. Schmidt, A. Polasik, J. Puppe, C. Mundhenke, K. Lübbe, T. Hesse, M. Thill, D-M. Zahm, C. Denkert, T. Fehm, V. Nekljudova, J. Rey, S. Loibl, V. Müller, I. Witzel
Journal: Annals of Oncology (2022)
162O Primary analysis from DS8201-A-U105: A 2-part, open label, phase Ib trial assessing trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing advanced breast cancer
Authors: E.P. Hamilton, C.L. Shapiro, V. Boni, M. Martin Jimenez, G. Del Conte, J. Cortés, L. Agrawal, H-T. Arkenau, A.R. Tan, P.R. Debruyne, A.R. Minchom, A. Rutten, F. Valdes-Albini, E. Yu, F. Suto, F-C. Cheng, B. Augustine, B. Cheng, D. Barrios, S.A. Hurvitz
Journal: Annals of Oncology (2022)
34P Quadruple-negative breast cancer (PD-L1-negative triple-negative breast cancer, TNBC): Poorer response to chemotherapy and poorer survival compared to other TNBCs: A systematic review and meta-analysis
Authors: L. Kassem, K.S. Shohdy, H. Elghazawy, M. Salib, D.S. Almeldin, H.A. Azim
Journal: Annals of Oncology (2022)
161O VIOLETTE: Randomised phase II study of olaparib (ola) + ceralasertib (cer) or adavosertib (ada) vs ola alone in patients (pts) with metastatic triple-negative breast cancer (mTNBC)
Authors: A. Tutt, Z. Nowecki, R. Szoszkiewicz, S-A. Im, H-T. Arkenau, A. Armstrong, W. Jacot, J.H. Kim, M. Webster, J. Balmana, S. Delaloge, N. Lukashchuk, R. Odegbami, E. Casson, A.B. Loembe, M.W. Drachsler, E.J. Dean, K. Punie
Journal: Annals of Oncology (2022)

Combining DNA damage response (DDR) inhibitors to inhibit multiple DDR pathways may enhance tumour cell death. Preclinical models show synergistic antitumour effects of ola (PARP1 inhibitor) + cer (ATR inhibitor) or ada (WEE1 inhibitor). VIOLETTE (NCT03330847), a phase 2 open-label study, evaluated ola ± cer or ada as 2nd–3rd line in pts with mTNBC. Randomisation was stratified within each arm by mutation status (BRCAm, non-BRCAm homologous recombination repair pathway mutations [HRRm], or no HRRm [non-HRRm]) based on a prospective central tumour test and prior platinum therapy. Pts received ola 300 mg BID, 28-d cycle; cer 160 mg d 1–7 + ola 300 mg BID (cer+ola), 28-d cycle; or ada 150 mg BID d 1–3, 8–10 + ola 200 mg BID (ada+ola), 21-d cycle. Primary study endpoint was progression-free survival (PFS). Secondary endpoints included objective response rate (ORR), safety, and tolerability. Ada+ola was discontinued early due to higher than expected grade ≥3 haematologic toxicity, which limited its interpretation. We focus on cer+ola vs ola. The sponsor stopped VIOLETTE after reviewing BRCAm stratum efficacy data. Of 273 pts (450 planned; median age: 53 y), 114 received ola, 112 cer+ola, and 47 ada+ola. Primary analyses showed no statistically significant difference in PFS for cer+ola vs ola (BRCAm: n=83; HR 1.02 [90% CI 0.63–1.66, P=0.94], HRRm: n=40; 0.54 [0.28–1.03, 0.13], non-HRRm: n=103; 0.76 [0.50–1.14, 0.30]). No statistically significant difference in ORR was seen for cer+ola vs ola in BRCAm (50% vs 44%) or HRRm (20% vs 15%). ORR was higher in non-HRRm for cer+ola (15%, n=8) vs ola (4%, n=2) (odds ratio 4.45; 90% CI 1.30–21.20, P=0.04). In all pts, nausea and anaemia were the most common adverse events (AEs). Grade ≥3 AEs: 36% ola, 47% cer+ola, 78% ada+ola. Details of exploratory and subgroup analyses will be presented. Cer+ola did not improve PFS vs ola as 2nd–3rd line for mTNBC. Clinical significance of higher ORR with cer+ola in non-HRRm pts is unclear. Cer+ola had a manageable safety profile consistent with known profiles of each. Further analyses may identify pts likely to benefit from each treatment.
Opportunities and counterintuitive challenges for decentralized clinical trials to broaden participant inclusion
Authors: Noah Goodson, Paul Wicks, Jayne Morgan, Leen Hashem, Sinéad Callinan, John Reites
Journal: npj Digital Medicine (2022)

Abstract Traditional clinical trials have often failed to recruit representative participant populations. Just 5% of eligible patients participate in clinical research. Participants, particularly those from minority groups, cite geographical constraints, mistrust, miscommunication, and discrimination as barriers. Here, an intersectional view of inclusion in clinical trials provides significant insights into the complex and counterintuitive challenges of trial design and participant recruitment. The US FDA have recently proposed that decentralized clinical trials (DCTs) might reduce barriers and appeal to a wider range of participants by reducing the costs and commitments required for patients to participate. While common sense and early evidence suggests that allowing participants to take part in trials at or near home has advantages in terms of convenience, travel, and perhaps even infection control, it remains to be seen if DCT approaches will yield significant improvements on participant inclusivity. Some digital studies aiming to be more inclusive on a single element of inclusion, such as race, have experienced unintended consequences in other elements, like education or gender. Implementing DCTs presents new challenges including the digital divide, the exclusion of certain tests and procedures, complexities of at-home medication delivery, and the need to build new infrastructure. We present a range of challenges and opportunities for researchers to adopt and adapt DCT approaches to create reliable evidence that applies to all of us.
POST-COLONOSCOPY COLORECTAL CANCER: INCIDENCE, CHARACTERISTICS AND PREDICTIVE FACTORS
Authors: S. Baile-Maxía, C. Mangas-Sanjuan, M. Alustiza, L. Medina-Prado, O. Murcia, N. Traversi, P. Zapater, F. De Vera, G. García, M.D. Picó, G. Belda, A. García-Herola, M.J. Poveda, J.C. Penalva, R. Jover
Journal: Endoscopy (2022)

Aims Post-colonoscopy CRC (PCCRC) has become an important quality indicator. Our aim was to determine its rate, characteristics, and associated factors.
ENDOSCOPIC ULTRASOUND-GUIDED ANTEGRADE STENTING IN BENIGN BILIARY DISEASE WITH ALTERED ANATOMY (ROUX-EN-Y) AND EXTREME AGE PATIENT
Authors: D. Luna-Rodriguez, A. Garcia-Sumalla, J. Velásquez-Rodriguez, C. Consiglieri, S. Maisterra, J.B Gornals
Journal: Endoscopy (2022)

A 91yo man with history of Roux-en-Y reconstruction was admitted due to acute cholangitis. Cholangio-MRI: choledocholitiasis with intra and extrahepatic bile duct dilatation. A linear echoendoscope was used to perform an endoscopic biliary drainage. Firstly, EUS-guided biliary accesses by transgastric puncture of left intrahepatic biliary radical, confirmed by serum-instillation and bile-aspiration. Secondly, advancement of a guidewire anterogradely until reach enteral loop, through the papilla y by fluoroscopy-guidance. Finally, a transgastric-hepatic ostomy using a 6-Fr cystotome, and antegrade papilloplasty using a CRE balloon allowed a EUS-guided antegrade stenting (Biliary fully-covered metal stent, 60 x 10mm) without incidences.
ENDOSCOPIC ULTRASOUND (EUS)-GUIDED REPERMEABILIZATION WITH AN ENTERAL STENT THROUGH A GASTROENTERIC LUMEN-APPOSING METAL STENT (LAMS) BURIED BY TUMOR OVERGROWTH
Authors: B. Burgueño, C. Chavarria, E. Fuentes-Valenzuela, R. Sánchez-Ocaña, M. De Benito-Sanz, A. Carbajo-López, C. de la Serna-Higuera, M. Perez-Miranda
Journal: Endoscopy (2022)

EUS guided-gastroenterostomy for unresectable gastric antrum cancer resulted in recurrent gastric outlet obstruction and LAMS dysfunction due to tumor overgrowth 5-months later. A partially-covered duodenal metal stent was placed to clear retained gastric contents and to facilitate enteroclysis. The buried LAMS lumen was punctured under EUS from the stomach, a guidewire passed through the needle into the jejunum, and an enteral covered metal stent deployed OTW across the LAMS. The patient was discharged uneventfully with adequate soft oral intake reinitiating chemotherapy.
INFLUENCE OF COVID-19 ON PATIENTS UNDER PROPHYLACTIC ENDOSCOPIC VARICEAL LIGATION (EVL) THERAPY IN A PORTUGUESE CENTER
Authors: A. Craciun, I. Botto, J. Lopes, M. Moura, S. Carvalhana, L. Carrilho-Ribeiro, R. Tato Marinho
Journal: Endoscopy (2022)

Aims Evaluate the impact of COVID-19 on outcomes of patients under prophylactic EVL therapy, namely variceal eradication, bleeding post-EVL therapy and death at 6 months post-last session.
HOW TO OPTIMIZE STANDARD OF CARE FOR PANCREATOBILIARY DISEASES: A NATIONWIDE ANALYSIS
Authors: C. Coluccio, L. Archibugi, M.C. Conti Bellocchi, M. Falconi, S.F. Crinò, G. Capurso, C. Fabbri, G. Aisp
Journal: Endoscopy (2022)

Aims Aim of this survey is to investigate the current clinical and therapeutic management of patients affected by pancreatobiliary diseases nationwide, with the purpose to identify the key points needing to be strengthened, focusing on clinical outcome optimization.
REDUCTION IN THE NUMBER OF ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHIES PERFORMED IN BRAZIL DURING THE COVID-19 PANDEMIC
Authors: T. Correa
Journal: Endoscopy (2022)

Aims Considering the high transmissibility of COVID-19, health systems can become overwhelmed and the lack of resources is a major concern in low- and middle-income countries including Brazil. The number of endoscopic retrograde cholangiopancreatographies (ERCPs) performed may be impacted by the health system oversaturation due to COVID-19. The aim of this study was to evaluate the number of ERCPs performed in Brazil during the COVID-19 pandemic.
SARS-CoV-2 Omicron variant BA.2 neutralisation in sera of people with Comirnaty or CoronaVac vaccination, infection or breakthrough infection, Hong Kong, 2020 to 2022
Authors: Samuel MS Cheng, Chris Ka Pun Mok, Karl CK Chan, Susanna S Ng, Bosco HS Lam, Leo LH Luk, Fanny W Ko, Chunke Chen, Karen Yiu, John KC Li, Ken KP Chan, Leo CH Tsang, Leo LM Poon, David SC Hui, Malik Peiris
Journal: Eurosurveillance (2022)

BackgroundOmicron subvariant BA.2 circulation is rapidly increasing globally.AimWe evaluated the neutralising antibody response from vaccination or prior SARS-CoV-2 infection against symptomatic infection by BA.2 or other variants.MethodsUsing 50% plaque reduction neutralisation tests (PRNT
Inhibition of FGF receptor blocks adaptive resistance to RET inhibition in <i>CCDC6-RET</i>–rearranged thyroid cancer
Authors: Renuka Raman, Jacques A. Villefranc, Timothy M. Ullmann, Jessica Thiesmeyer, Viviana Anelli, Jun Yao, James R. Hurley, Chantal Pauli, Rohan Bareja, Kenneth Wha Eng, Princesca Dorsaint, David C. Wilkes, Shaham Beg, Sarah Kudman, Reid Shaw, Michael Churchill, Adnan Ahmed, Laurel Keefer, Ian Misner, Donna Nichol, Naveen Gumpeni, Theresa Scognamiglio, Mark A. Rubin, Carla Grandori, James Patrick Solomon, Wei Song, Juan Miguel Mosquera, Noah Dephoure, Andrea Sboner, Olivier Elemento, Yariv Houvras
Journal: The Journal of Experimental Medicine (2022)

Genetic alterations in RET lead to activation of ERK and AKT signaling and are associated with hereditary and sporadic thyroid cancer and lung cancer. Highly selective RET inhibitors have recently entered clinical use after demonstrating efficacy in treating patients with diverse tumor types harboring RET gene rearrangements or activating mutations. In order to understand resistance mechanisms arising after treatment with RET inhibitors, we performed a comprehensive molecular and genomic analysis of a patient with RET-rearranged thyroid cancer. Using a combination of drug screening and proteomic and biochemical profiling, we identified an adaptive resistance to RET inhibitors that reactivates ERK signaling within hours of drug exposure. We found that activation of FGFR signaling is a mechanism of adaptive resistance to RET inhibitors that activates ERK signaling. Combined inhibition of FGFR and RET prevented the development of adaptive resistance to RET inhibitors, reduced cell viability, and decreased tumor growth in cellular and animal models of CCDC6-RET–rearranged thyroid cancer.
REPEATED EUS-GUIDED FINE NEEDLE BIOPSY AFTER NON-DIAGNOSTIC OR INCONCLUSIVE RESULTS OF SOLID PANCREATIC MASSES – THE REUBIO STUDY
Authors: A. Cominardi, A. Lisotti, S.F. Crinò, A. Larghi, A. Facciorusso, C. Fabbri, H. Bertani, C. De Angelis, F.M. Di Matteo, A. Pisani, M.L. Brancaccio, E. Dabizzi, A. Grillo, A. Fantin, A. Pezzoli, F. Decembrino, A. Amato, T. Togliani, F. Antonini, A. Montale, E. Forti, V. Cennamo, M. Manno, S. Carrara, P.G. Arcidiacono, B. Mangiavillano, C. Binda, G. Aragona, A. Mussetto, M.C. Conti Bellocchi, S. Stigliano, E. Gasparini, G. Rizzatti, M.G. Pellegrino, N. Muscatiello, G. Marocchi, S. Mangiafico, M. Lupo, O. Burattini, R. Lovero, S. Fabbri, E. Dall'Amico, F. D'Errico, T. Gabbani, R.M. Zagari, P. Fusaroli
Journal: Endoscopy (2022)

Aims To evaluate the diagnostic yield of repeated EUS-FNB(rEUS-FNB) of pancreatic masses after previous non-diagnostic or inconclusive EUS-tissue acquisition(EUS-TA).
ENDOSCOPIC ULTRASOUND-GUIDED LIVER BIOPSY: A SAFE AND EFFECTIVE CHOICE IN THE STUDY OF HEPATIC DISEASES
Authors: V. Marquina, X. Andújar, A. Raga, A. Martin-Cardona, D. Horta, C. Báez, C. González, M. Esteve, F. Fernández-Bañares
Journal: Endoscopy (2022)

Aims Percutaneous liver biopsy has been considered as the main technique for liver diseases anatomopathological diagnosis. Endoscopic ultrasound-guided liver biopsy (EUS-LB) has been reported as an alternative. The aim is to evaluate the diagnostic yield, related factors and the safety of the EUS-LB.
149P Associations between the 313-SNP polygenic risk score and breast cancer risk in women from Crete
Authors: K. Yiangou, A. Hadjisavvas, S. Agelaki, D. Aggouraki, N. Androulakis, V. Bozionelou, I. Drositis, K. Kalmpakis, A. Kalykaki, E. Kontopodis, A. Kotsakis, E. Politaki, G. Saloustrou, L. Vamvakas, N.K. Vardakis, V. Georgoulias, D. Mavroudis, K. Michailidou, E. Saloustros
Journal: Annals of Oncology (2022)

Polygenic risk scores (PRS) developed for women of European ancestry could be used for the prediction of individualized breast cancer risk, and thus, potentially have applications in guiding targeted preventative measures and population screening. However, the PRS performance across diverse populations within Europe has not been extensively evaluated. This, is crucial before the use of PRS for clinical decisions. In this study, we aimed to evaluate the predictive performance of the 313-SNP PRS (PRS313) developed for women of European ancestry, in women from the Greek island of Crete, using 667 female breast cancer cases and 332 female controls from the Crete Cancer Genetics Program (CCGP study). PRS was calculated for each individual using the ln OR of the risk allele of every SNP taken from Mavaddat et al 2019. We evaluated for associations between PRS313 and overall breast cancer risk and by estrogen receptor (ER) status, as well as by quartiles of PRS313 risk distribution, using the 25-50th quartile as reference. The discriminatory ability of PRS313 was evaluated by calculating the area under the receiver operating characteristic curve (AUC). PRS313 was associated with an increased overall and ER-specific breast cancer risk, with OR (95% CI) 2.40 (1.92-3.03), p-value = and AUC = 0.653 for overall breast cancer, OR (95% CI) 2.72 (2.16-3.47), p-value = and AUC = 0.681 for ER-positive disease and OR (95% CI) 2.18 (1.58-3.03), p-value = and AUC = 0.628 for ER-negative disease. Women in the lowest quartile of PRS313 risk distribution had a 0.66-fold, 0.54-fold, and 0.89-fold risk; while those in the highest quartile had a 2.73–fold, 3.11-fold, and 2.74-fold risk for overall, ER-positive and ER-negative disease respectively, compared to women in the reference quartile. These results provide evidence that PRS313 could stratify women from Crete according to their individualized overall and ER-specific breast cancer risk, at the extreme quartiles. Combination of PRS313 with classical risk factors could potentially provide a more comprehensive risk prediction and thus improve risk stratification of Cretan women. If these results are confirmed in a bigger dataset, then PRS313 has the potential for further clinical evaluation.
191P Radiotherapy (RT) in oligoprogressive metastatic breast cancer (mBC): A retrospective analysis
Authors: F. Marazzi, A. Orlandi, V. Masiello, T. Zinicola, F. Moschella, A. Palazzo, S. Chiesa, G. Garufi, V. Frascino, L. Tagliaferri, G. Franceschini, A. Fabi, M.A. Gambacorta, E. Bria, R. Masetti, G. Tortora, V. Valentini
Journal: Annals of Oncology (2022)
AMPULLECTOMY OF A TRADITIONAL SERRATED ADENOMA
Authors: A.J. del Pozo-Garcia, J.C. Marín-Gabriel, P. Hernán, F. Sánchez-Gómez
Journal: Endoscopy (2022)

During dyspepsia investigation a big (over 3-cm) sessile (Paris 0-Is) duodenal ampullary lesion was found by upper endoscopy. Regular margins, absence of spontaneous bleeding, both suggesting benignity. Biopsies: papillary tubulovillous adenoma with low-grade dysplasia. EUS: mucosal layer lesion, intermediate echogenicity, no intraductal biliary or pancreatic growing and absence of lymphadenopaties. A snare ampullectomy was performed, followed by sphyncterotomy, double stenting. and argon-ablation of the margins; discharged in 48 hours. Pathology: traditional serrated adenoma with high-grade dysplasia foci and no invasion of lamina propria or submucosa. No 6-month recurrence.
SAFETY AND FEASIBILITY OF LUMEN-APOSSING METAL STENTS REMOVALS. RESULTS FROM A PROSPECTIVE NATIONWIDE REGISTRY
Authors: S. Bazaga, F.J. Garcia-Alonso, J.R. Aparicio Tormo, B. Martinez Moreno, V. Sanchiz, C. Suria, A. Garcia-Sumalla, J.B Gornals, C. Loras, C. Chavarría, F.J. García-Fernandez, Á. Terán, E. Vazquez-Sequeiros, R. Pedraza Sanz, L. Pérez-Carazo, J.C. Súbtil, A. Pérez-Millan, F. Uceda Porta, V. Busto Bea, C. de la Serna-Higuera, I. Pinto García, J. Colán-Hernández, C. Huertas, A. Vilella Martorell, A. Guardiola-Arévalo, J.L. Castro Urda, J. Nuñez-Otero, E. Sánchez-Hernández, F. Gonzalez-Huix, F. de la Morena, R. Villanueva Pavón, I. Couto-Worner, C. Guarner-Argente, M. Perez-Miranda
Journal: Endoscopy (2022)

Aims Lumen-apposing metal stents (LAMS) removals are performed in advanced endoscopy suites equipped with fluoroscopy. Studies assessing the removal complexity, technique and adverse events (AEs) are lacking.
ADVANCED TECHNOLOGY FOR ASSESSMENT OF ENDOSCOPIC AND HISTOLOGICAL REMISSION IN ULCERATIVE COLITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS
Authors: O.M. Nardone, Y. Snir, J. Hodson, R. Cannatelli, N. Labarile, K. Siau, C. Hassan, H. Yanai, I. Dotan, S. Ghosh, M. Iacucci
Journal: Endoscopy (2022)

Aims Advanced endoscopic technologies led to significant progress in the definition of endoscopic remission of ulcerative colitis (UC), and correlate better with histological changes, compared to standard endoscopy. However, whilst studies have assessed the diagnostic accuracy of endoscope technologies individually, there is current limited data comparing between technologies. As such, the aim of this systematic review was to compare the correlations between endoscopy and histology disease activity scores across endoscope technologies